Antibody-mediated targeting of TNFR2 activates CD8
Animals
Antibodies, Monoclonal
/ immunology
CD8-Positive T-Lymphocytes
/ drug effects
Colonic Neoplasms
/ immunology
Disease Models, Animal
Female
Humans
Lymphocyte Activation
/ drug effects
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Receptors, Tumor Necrosis Factor, Type II
/ antagonists & inhibitors
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
02 10 2019
02 10 2019
Historique:
received:
19
02
2019
revised:
22
05
2019
accepted:
16
08
2019
entrez:
4
10
2019
pubmed:
4
10
2019
medline:
15
9
2020
Statut:
ppublish
Résumé
Tumor necrosis factor receptor 2 (TNFR2) is the alternate receptor for TNF and can mediate both pro- and anti-inflammatory activities of T cells. Although TNFR2 has been linked to enhanced suppressive activity of regulatory T cells (T
Identifiants
pubmed: 31578241
pii: 11/512/eaax0720
doi: 10.1126/scitranslmed.aax0720
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Receptors, Tumor Necrosis Factor, Type II
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P41 CA196276
Pays : United States
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.